Literature DB >> 1969518

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

S MacMahon1, R Peto, J Cutler, R Collins, P Sorlie, J Neaton, R Abbott, J Godwin, A Dyer, J Stamler.   

Abstract

The associations of diastolic blood pressure (DBP) with stroke and with coronary heart disease (CHD) were investigated in nine major prospective observational studies: total 420,000 individuals, 843 strokes, and 4856 CHD events, 6-25 (mean 10) years of follow-up. The combined results demonstrate positive, continuous, and apparently independent associations, with no significant heterogeneity of effect among different studies. Within the range of DBP studied (about 70-110 mm Hg), there was no evidence of any "threshold" below which lower levels of DBP were not associated with lower risks of stroke and of CHD. Previous analyses have described the uncorrected associations of DBP measured just at "baseline" with subsequent disease rates. But, because of the diluting effects of random fluctuations in DBP, these substantially underestimate the true associations of the usual DBP (ie, an individual's long-term average DBP) with disease. After correction for this "regression dilution" bias, prolonged differences in usual DBP of 5, 7.5, and 10 mm Hg were respectively associated with at least 34%, 46%, and 56% less stroke and at least 21%, 29%, and 37% less CHD. These associations are about 60% greater than in previous uncorrected analyses. (This regression dilution bias is quite general, so analogous corrections to the relations of cholesterol to CHD or of various other risk factors to CHD or to other diseases would likewise increase their estimated strengths.) The DBP results suggest that for the large majority of individuals, whether conventionally "hypertensive" or "normotensive", a lower blood pressure should eventually confer a lower risk of vascular disease.

Entities:  

Mesh:

Year:  1990        PMID: 1969518     DOI: 10.1016/0140-6736(90)90878-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  801 in total

1.  Safety profile of lacidipine: update from a clinical trials database.

Authors:  L H Lindholm; P Tcherdakoff; A Zanchetti
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  The role of diet in the prevention and treatment of hypertension.

Authors:  L J Appel
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

Review 3.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

4.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

5.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 6.  Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

Authors:  N Chapman; B Neal
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 7.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 8.  Sleep apnoea and hypertension: proof at last?

Authors:  J R Stradling; J C Pepperell; R J Davies
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

9.  Problems in the control of systolic blood pressure.

Authors:  L M Ruilope
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 10.  Diastolic pressure, systolic pressure, or pulse pressure?

Authors:  C Vlachopoulos; M O'Rourke
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.